Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Amicus Therapeutics (FOLD) over the last 16 years, with Q3 2025 value amounting to $1.9 million.

  • Amicus Therapeutics' Depreciation & Amortization (CF) fell 1364.06% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year decrease of 1247.7%. This contributed to the annual value of $8.5 million for FY2024, which is 856.09% up from last year.
  • Latest data reveals that Amicus Therapeutics reported Depreciation & Amortization (CF) of $1.9 million as of Q3 2025, which was down 1364.06% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Depreciation & Amortization (CF) ranged from a high of $2.2 million in Q3 2023 and a low of $1.3 million during Q1 2023
  • In the last 5 years, Amicus Therapeutics' Depreciation & Amortization (CF) had a median value of $1.8 million in 2025 and averaged $1.8 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first crashed by 4040.05% in 2021, then soared by 7325.04% in 2023.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Depreciation & Amortization (CF) stood at $1.5 million in 2021, then fell by 13.64% to $1.3 million in 2022, then soared by 66.44% to $2.2 million in 2023, then dropped by 6.46% to $2.0 million in 2024, then fell by 8.18% to $1.9 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $1.9 million for Q3 2025, versus $1.9 million for Q2 2025 and $1.8 million for Q1 2025.